68755-30-6

Basic information

• Product Name: 6,7-dichloro-2,3-dihydro-1H-inden-1-one
• Synonyms: 6,7-dichloro-2,3-dihydro-1H-inden-1-one
• CAS NO: 68755-30-6
• Molecular Formula: C9H6Cl2O
• Molecular Weight: 201
• Mol File: 68755-30-6.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 6,7-dichloro-2,3-dihydro-1H-inden-1-one(CAS DataBase Reference)
• NIST Chemistry Reference: 6,7-dichloro-2,3-dihydro-1H-inden-1-one(68755-30-6)
• EPA Substance Registry System: 6,7-dichloro-2,3-dihydro-1H-inden-1-one(68755-30-6)

Safety Data

• Hazardous Substances Data: 68755-30-6(Hazardous Substances Data)

Usage

General Description

6,7-dichloro-2,3-dihydro-1H-inden-1-one is a chemical compound with the molecular formula C9H6Cl2O. It is a yellow solid substance that is primarily used in the synthesis of other organic compounds. This chemical is often utilized in the development of pharmaceuticals, agrochemicals, and other fine chemicals. It is also known for its ability to act as an intermediate in the production of various types of perfumes and flavoring agents. Additionally, 6,7-dichloro-2,3-dihydro-1H-inden-1-one is also used as a research chemical for its unique properties and potential applications in various industries.

InChI:InChI=1S/C9H6Cl2O/c10-6-3-1-5-2-4-7(12)8(5)9(6)11/h1,3H,2,4H2

Upstream product

• 74-85-1 ethene 
• 50-45-3 2,3-dichlorbenzoic acid 
• 90273-67-9 3-(3,4-dichlorophenyl)propionic acid chloride 
• 25173-68-6 3(3,4-dichlorophenyl)propanoic acid 
• 69392-64-9 4,5-dichloroindan-1-one 

Downstream Products

• 68755-31-7 5,6-dichloro-2,3-dihydro-1H-inden-1-one 

Relevant articles and documents

Discovery and Optimization of 1-Phenoxy-2-aminoindanes as Potent, Selective, and Orally Bioavailable Inhibitors of the Na+/H+ Exchanger Type 3 (NHE3)

The design, synthesis, and structure-activity relationship of 1-phenoxy-2-aminoindanes as inhibitors of the Na+/H+ exchanger type 3 (NHE3) are described based on a hit from high-throughput screening (HTS). The chemical optimization resulted in the discovery of potent, selective, and orally bioavailable NHE3 inhibitors with 13d as best compound, showing high in vitro permeability and lacking CYP2D6 inhibition as main optimization parameters. Aligning 1-phenoxy-2-aminoindanes onto the X-ray structure of 13d then provided 3D-QSAR models for NHE3 inhibition capturing guidelines for optimization. These models showed good correlation coefficients and allowed for activity estimation. In silico ADMET models for Caco-2 permeability and CYP2D6 inhibition were also successfully applied for this series. Moreover, docking into the CYP2D6 X-ray structure provided a reliable alignment for 3D-QSAR models. Finally 13d, renamed as SAR197, was characterized in vitro and by in vivo pharmacokinetic (PK) and pharmacological studies to unveil its potential for reduction of obstructive sleep apneas.

CYCLIC AMINE DERIVATIVE OR SALT THEREOF

Provided are compounds which are an NMDA antagonist having a broad safety margin and are useful as a treating agent or a preventing agent for Alzheimer's disease, cerebrovascular dementia, Parkinson's disease, ischemic apoplexy, pain, etc. Concretely prov

4-SUBSTITUTED IMIDAZOLE-2-THIONES AND IMIDAZOL- 2-ONES AS AGONISTS OF THE ALPHA- 2B AND ALPHA-2C ADRENERGIC RECEPTORS

Compounds of Formula (I): where X is S and the variables have the meaning defined in the specification are specific or selective to alpha2B and/or alpha2C adrenergic receptors in preference over alpha2A adrenergic receptors, and as such have no or only minimal cardivascular and/or sedatory activity. These compounds of Formula (I) are useful as medicaments in mammals, including humans, for treatment of diseases and or alleviations of conditions which are responsive to treatment by agonists of alpha2B adrenergic receptors. Compounds of Formula (I) where X is O also have the advantageous property that they have no or only minimal cardivascular and/or sedatory activity and are useful for treating pain and other conditions with no or only minimal cardivascular and/or sedatory activity.